The use of Probiotics has been notably discussed and pointed out by the Science Community as an alternative solution for tackling inflammatory chronic diseases, instead of anti-inflammatory drugs and antibiotics, which produce strong side effects. In this context, since the 19th century, Lactic Acid Bacteria, mainly Lactobacillus genus, have been mostly investigated, representing the majority of microbes with the ability to promote human health. Novel strains of bacteria and yeasts are being isolated every day from different sources bringing up a plethora of potential probiotic features to be explored. Moreover, new species of commensal bugs are being isolated from the human gut, referred to as the “next generation probiotics”, such as Faecalibacterium prausnitzii and Akkermansia muciniphila, which plays fundamental roles in homeostasis but much little is known about their mechanism of action and molecular bases. In the last decades, the advent of high throughput molecular methods and OMICS approaches have greatly assisted the search for strain-dependent probiotic features by allowing thousands of strains to be investigated every year.
arch topic aims to publish original research and review articles on the use of OMICS approaches either to characterize novel strains or species with potential probiotic applications, including bacteria, archaea and yeasts or to unravel mechanisms of action involved in human health promotion, such as increased persistence in the colonization process, biofilm formation, gut microbiota modulation, secretion of antimicrobial peptides, production of biosurfactants and anti-inflammatory compounds.
Editors welcome original research and review articles on topics related but not limited to the following areas:
• Comparative Genomics as a tool for identifying and characterizing novel probiotic bacteria, archaea and yeasts;
• Drug discovery study based on computational methods (i.e. molecular docking) for targeting host microbiota or designing microorganism-derived compounds for the treatment of chronic diseases (non-clinical studies only);
• Integrative multi-omics applied to systems biology investigating mechanisms of action of beneficial microbes associated with human health.
The use of Probiotics has been notably discussed and pointed out by the Science Community as an alternative solution for tackling inflammatory chronic diseases, instead of anti-inflammatory drugs and antibiotics, which produce strong side effects. In this context, since the 19th century, Lactic Acid Bacteria, mainly Lactobacillus genus, have been mostly investigated, representing the majority of microbes with the ability to promote human health. Novel strains of bacteria and yeasts are being isolated every day from different sources bringing up a plethora of potential probiotic features to be explored. Moreover, new species of commensal bugs are being isolated from the human gut, referred to as the “next generation probiotics”, such as Faecalibacterium prausnitzii and Akkermansia muciniphila, which plays fundamental roles in homeostasis but much little is known about their mechanism of action and molecular bases. In the last decades, the advent of high throughput molecular methods and OMICS approaches have greatly assisted the search for strain-dependent probiotic features by allowing thousands of strains to be investigated every year.
arch topic aims to publish original research and review articles on the use of OMICS approaches either to characterize novel strains or species with potential probiotic applications, including bacteria, archaea and yeasts or to unravel mechanisms of action involved in human health promotion, such as increased persistence in the colonization process, biofilm formation, gut microbiota modulation, secretion of antimicrobial peptides, production of biosurfactants and anti-inflammatory compounds.
Editors welcome original research and review articles on topics related but not limited to the following areas:
• Comparative Genomics as a tool for identifying and characterizing novel probiotic bacteria, archaea and yeasts;
• Drug discovery study based on computational methods (i.e. molecular docking) for targeting host microbiota or designing microorganism-derived compounds for the treatment of chronic diseases (non-clinical studies only);
• Integrative multi-omics applied to systems biology investigating mechanisms of action of beneficial microbes associated with human health.
